EmpiraMed Revenue and Competitors

EmpiraMed has created novel decentralized (or virtual) study patient-engagement software to generate Real World Evidence for the Life Science Industry. The EmpiraMed[TM] PRO Portal[TM] platform offers unsurpassed user “stickiness” to directly capture real world patient experience. Combining our fully automated study execution rules-engine, novel patient recruitment methods, and true mobile device independence, EmpiraMed delivers the most robust decentralized clinical trial solution available. To that end, most of our studies are 100% site-less, from patient recruitment to execution, which few vendors can claim. Our portal includes the ground-breaking Rewards Program which has improved patient engagement and study compliance to more than 3X current industry standards. In addition, our customers can now use this next-generation technology to file new indications for regulatory approval under the EmpiraMed DESTINI[TM] program, which is designed to reduce costs, expand patient access, and shorten time to market. To support Post Market Required Phase IV Studies, EmpiraMed has developed the PMR Portal[TM] Patient Medical Record System to capture clinic routine care data while eliminating reliance on clinic visits. By adding our partners who offer home visits, interventional clinical trials can be performed with our platform without any clinical sites whatsoever. EmpiraMed’s software and services support all industry compliance requirements including HIPAA, GDPR, 21 CFR Part 11, and GCP. Studies can be internationalized using our automated, rules-based, localization system. Our customers have included prominent biopharmaceutical manufacturers such as Merck Sharp & Dohme, Biogen, Janssen, Sanofi Genzyme, United Therapeutics, Teva, and Takeda. We also have contracts with leading Patient Advocacy Groups, such as LUNGevity, and novel patient recruitment channels, including CVS Specialty and Optum Specialty, to offer a unique and broad decentralized study solution.